0TDD Stock Price and Chart — LSE:0TDD

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

Analysts warn that lower U.S. drug prices threaten pharmaceutical firms like Novo Nordisk, which depends on U.S. sales. This pressure could cut R&D spending and hinder long-term innovation.

Novo Nordisk's weight-loss drug Wegovy is reshaping the weight management market, contributing to the bankruptcy of traditional programs like WeightWatchers amid the surge in GLP-1 agonist use.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.